Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Suzanne Louise Topalian, Charles G. Drake, Drew M. Pardoll · Current Opinion in Immunology · 2012
Cited by 1,329 works. doi:10.1016/j.coi.2011.12.009
Authors
References
- Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
- Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
- Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor
- B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
- Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.
- PD-1 and Its Ligands in Tolerance and Immunity
- Restoring function in exhausted CD8 T cells during chronic viral infection
- PD-L2 is a second ligand for PD-1 and inhibits T cell activation